Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Beneficial gut bacteria refers to non-pathogenic microbial taxa in the human gastrointestinal tract that contribute to host health through diverse biological functions, including digesting food, synthesizing vitamins, preventing infection, and modulating immune responses. Prominent examples include *Lactobacillus* and *Bifidobacterium* species, as well as butyrate-producing genera like *Roseburia*. Therapeutic interventions may supplement or promote beneficial bacteria via probiotics, prebiotics, microbiome-targeted drugs, or dietary strategies. However, "beneficial gut bacteria" is not a single molecule or receptor and cannot serve as a classical therapeutic target in the context of molecular pharmacology. Note: For structured data, mapping should be to specific bacterial species or genetically defined strains (e.g., "Lactobacillus rhamnosus GG"), not this broad functional group.
Colonization resistance (inhibiting pathogens); Modulation of host immune responses; Production of antimicrobial metabolites (e.g., bacteriocins); Fermentation of dietary fibers into short-chain fatty acids; Enhancement of gut barrier function
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Beneficial gut bacterium.